
At the time of market authorization and/or the expansion of indication of new zzso drugs, it is often not possible to reliably measure the relevant benefit for the zzso The conception of the clinical studies, on which the market authorization and/or expansion of indication is based, zzso itself primarily at the regulatory requirements of the regulatory zzso In addition, their results are frequently published only incompletely or some time after the end of the clinical zzso To clarify these outstanding questions regarding the individual treatment of patients, zzso clinical studies after the market authorization are zzso However, the execution of these studies is zzso due to insufficient financial means as well as by regulations and the low evaluation of such studies by the zzso Further challenges result from the high costs of innovative zzso therapies, which burden the resources of the statutory and private health insurance zzso zzso who are confronted with an aging population and a rising prevalence of tumor zzso Independent zzso authorization clinical studies need to be completed in order to ensure a zzso and efficient treatment with new zzso zzso New perspectives result by connecting the reimbursement of the costs of innovative therapies by the zzso and zzso to the generation of evidence in the context of clinical studies, thus improving the medical care of tumor patients as well as the efficient handling of limited health zzso 

